Optimization of MRI Sequences Used in the Study of Neurodegenerative Diseases

NCT05929144 | Recruiting

• 2 other identifiers: 23-00302023-A00398-37
• Study Type: interventional
• Target: 40
• Locations: 1 country
• Sites: 1

Brief Summary

The Inserm NeuroPresage team has been using MRI for more than 20 years in the study of normal ageing and memory pathologies to further the understanding and the characterization of early diagnosis and the cerebral substrates of cognitive deficits in patients, particularly in the context of neurodegenerative diseases. Two years ago, a new 3T MRI camera was installed at the Cyceron centre. It is more efficient and should make it possible to obtain better quality images and/or to reduce the time required to acquire these images. In this context, it seems important to test the different sequences that we classically use in our studies, or that we plan to implement in our next studies (learning and text retrieval fMRI task), in order to optimize them, with a view to integrating them in our future studies.

Conditions

Memory Disorders

Outcome Measures

Primary Outcomes (1)

• Optimization of MRI sequences

  TR, TE, Flip Angle, asset phase, asset slice parameters

  During MRI sessions

Study Arms (1)

Healthy volunteers

OTHER

Other: MRI sequences testing

Interventions

MRI sequences testing OTHER

Testing different MRI sequences in order to optimize them

Healthy volunteers

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Healthy volunteers of legal age
• Affiliation with a social security scheme or beneficiary of such a scheme
• Signing of the protocol informed consent

You may not qualify if:

• Protected persons in accordance with articles L. 1121-5 to L.1121-8 of the Public Health Code: protected adults, pregnant and nursing women
• Presence of contraindications to MRI examination without contrast agents injection
• Presence of a chronic neurological or psychiatric condition (including substance use disorder)
• History of brain disease (vascular, degenerative, malformative, tumour, or head trauma with loss of consciousness for more than one hour)
• Current or recent use of medications that may interfere with imaging (psychotropic drugs, antihistamines with anticholinergic action, antiparkinsonian drugs, benzodiazepines including muscle relaxants, long-term steroidal anti-inflammatory drugs, antiepileptic drugs, central painkillers)

Sponsors & Collaborators

• University Hospital, Caen: lead

Study Sites (1)

GIP Cyceron

Caen, 14000, France

RECRUITING

MeSH Terms

Conditions

Memory Disorders

Condition Hierarchy (Ancestors)

Neurobehavioral Manifestations; Neurologic Manifestations; Nervous System Diseases; Signs and Symptoms; Pathological Conditions, Signs and Symptoms

Study Officials

• Gaël Chételat, PhD

  Institut National de la Santé Et de la Recherche Médicale, France

  STUDY DIRECTOR

• Nicolas Cabé, MD, PhD

  CHU Caen Normandie

  PRINCIPAL INVESTIGATOR

Central Study Contacts

Géraldine Poisnel, PhD

CONTACT

0231470206; poisnel@cyceron.fr

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: NA
• Masking: NONE
• Purpose: OTHER
• Intervention Model: SINGLE GROUP
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: May 25, 2023
• First Posted: July 3, 2023
• Study Start: May 5, 2023
• Primary Completion (Estimated): July 1, 2028
• Study Completion (Estimated): July 1, 2028
• Last Updated: July 3, 2023

Record last verified: 2023-05

Data Sharing

• IPD Sharing: Will not share

Locations

FR (1)